Precision BioSciences doses first patient in Phase 1/2 FUNCTION-DMD gene editing trial

PRECISION BIOSCIENCES INC

First patient dosed with PBGENE-DMD, first clinical gene-editing program for DMD, at Arkansas Children's Hospital.
PBGENE-DMD excises exons 45-55 to restore near full-length dystrophin; applicable to up to 60% of DMD patients.
Trial enrolling ambulatory DMD patients aged 2-7 with mutations between exons 45-55; initial safety data expected by year-end 2026.
PBGENE-DMD is wholly owned in vivo program using ARCUS platform; aims to durably improve function.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.